KaydedilenlerDerginizi ekleyin

Dergiler / Eurasian Journal of Emergency Medicine / 2016 / Cilt: 15 - Sayı: 1

Can Serum Surfactant Protein D Levels be used as an Effective Factor Instead of Clinical Severity Scores of Pneumonia in Pediatric Emergency Departments?

Mehmet AÇIKGÖZ
Naci MURAT
Bülent ŞİŞMAN
Şükrü PAKSU
Ahmet GÜZEL
Adil KARADAĞ
Sayfa
1–6
Yayın Tarihi
2022-10-11
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

The serum SP-D levels of the patient group were significantly higher than those of the control group (p

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Aim: To investigate whether serum surfactant protein D (SP-D) level is an applicable indicator in differentiating bacterial and viral pneumonia and determining clinical severity in cases with community-acquired pneumonia (CAP).Materials and Methods: A total of 67 subjects were analyzed prospectively; of these, 32 were patients (aged 1 month-18 years) with a diagnosis of CAP and 35 were healthy control subjects.Results: The median age of the patients was 17.5 months (1.5-156 months).
📊
Temel Bulgular & Veri:Aim: To investigate whether serum surfactant protein D (SP-D) level is an applicable indicator in differentiating bacterial and viral pneumonia and determining clinical severity in cases with community-acquired pneumonia (CAP).Materials and Methods: A total of 67 subjects were analyzed prospectively; of these, 32 were patients (aged 1 month-18 years) with a diagnosis of CAP and 35 were healthy control subjects.Results: The median age of the patients was 17.5 months (1.5-156 months).
💡
Sonuç & Katkı:The serum SP-D levels of the patient group were significantly higher than those of the control group (p
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

Aim: To investigate whether serum surfactant protein D (SP-D) level is an applicable indicator in differentiating bacterial and viral pneumonia and determining clinical severity in cases with community-acquired pneumonia (CAP).Materials and Methods: A total of 67 subjects were analyzed prospectively; of these, 32 were patients (aged 1 month-18 years) with a diagnosis of CAP and 35 were healthy control subjects.Results: The median age of the patients was 17.5 months (1.5-156 months). The serum SP-D levels of the patient group were significantly higher than those of the control group (p

🔖

Bu Makaleye Atıf Yap

AÇIKGÖZ, M., MURAT, N., ŞİŞMAN, B., PAKSU, Ş., GÜZEL, A., KARADAĞ, A. (2022). Can Serum Surfactant Protein D Levels be used as an Effective Factor Instead of Clinical Severity Scores of Pneumonia in Pediatric Emergency Departments?. Eurasian Journal of Emergency Medicine, Cilt: 15 - Sayı: 1, 1–6. https://ajindex.com/articles/508149

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (5)

  1. Esposito S, Principi N. Pneumococcal vaccines and the prevention of community-acquired pneumonia. Pulm Pharmacol Ther 2014; 1094: 31-5.
  2. Rudan I, Boschi-Pinto C, Biloglav Z, Mulholland K, Campbell H. Epidemi- ology and etiology of childhood pneumonia. Bull World Health Organ 2008; 86: 408-16. [CrossRef] Tejani NR. Respiratory Disorders Bacterial pneumonia. In: Binita R. Shah, eds, Atlas of pediatric emergency. 2th ed. New York: The McGraw-Hill Companies, 2013; 205-8.
  3. Cardinale F, Cappiello AR, Mastrototaro MF, Pignatelli M, Esposito S. Com- munity-acquired pneumonia in children. Early Hum Dev 2013; 89: 49-52. [CrossRef] Ruuskanen O, Lahti E, Jennings LC, Murdoch DR. Viral pneumonia. Lancet 2011; 377: 1264-75. [CrossRef] Haagsman HP, Hogenkamp A, van Eijk M, Veldhuizen EJ. Surfactant col- lectins and innate immunity. Neonatology 2008; 93: 288-94. [CrossRef] Kotecha S, Doull I, Davies P, McKenzie Z, Madsen J, Clark HW, et al. Func- tional heterogeneity of pulmonary surfactant protein-D in cystic fibrosis. Biochim Biophys Acta 2013: 2391-400.
  4. Guzel A, Kanter M, Guzel A, Yucel AF, Erboga M. Protective effect of cur- cumin on acute lung injury induced by intestinal ischaemia/reperfusion. Health 2013; 29: 969. [CrossRef] Guzel A, Kanter M, Guzel A, Pergel A, Erboga M. Anti-inflammatory and antioxidant effects of infliximab on acute lung injury in a rat model of intestinal ischemia/reperfusion. J Mol Histol 2012; 43: 361-9. [CrossRef] World Health Organization: The Management of Acute Respiratory Infec- tions in Children. Practical Guidelines for Outpatient Care. Geneva: World Health Organization; 1995.
  5. Liu LL, Gallaher MM, Davis RL, Rutter CM, Lewis TC, Marcuse EK. Use of a respiratory clinical score among different providers. Pediatr Pulmonol 2004; 37: 243-8. [CrossRef] Harris M, Clark J, Coote N, Fletcher P, Harnden A, McKean M, et al. British Thoracic Society guidelines for the management of community acquired pneumonia in children: update 2011. Thorax 2011; 66(Suppl 2): ii1-23. Sorensen GL, Husby S, Holmskov U. Surfactant protein A and surfactant protein D variation in pulmonary disease. Immunobiology 2007; 212: 381-416. [CrossRef] Leth-Larsen R, Nordenbaek C, Tornoe I, Moeller V, Schlosser A, Koch C, et al. Surfactant protein D (SP-D) serum levels in patients with communi- ty-acquired pneumonia. Clin Immunol 2003; 108: 29-37. [CrossRef] Lim BL, Wang JY, Holmskov U, Hoppe HJ, Reid KB. Expression of the car- bohydrate recognition domain of lung surfactant prot